Combination Therapy With Rituximab and Low-Dose Cyclophosphamide and Prednisone in Membranous Nephropathy

Area of Science:

• Nephrology
• Immunology
• Pharmacology

Background:

• Standard treatments for membranous nephropathy (MN) using cyclophosphamide (CP) or rituximab (RTX) show suboptimal efficacy.
• High-risk patients with MN are often positive for anti-PLA2R antibodies (PLA2Rab).

Purpose of the Study:

• To evaluate the efficacy of a low-dose triple therapy regimen (RTX, CP, prednisone) in high-risk PLA2Rab-positive MN patients.
• To analyze the kinetics of PLA2Rab levels and their correlation with clinical and immunological remission.

Main Methods:

• A single-arm prospective cohort study involving 26 high-risk PLA2Rab-positive MN patients.
• Treatment included a modified low-dose regimen of RTX, CP, and prednisone.
• Regular measurement of PLA2Rab levels, serum creatinine, albumin, and urinary protein-to-creatinine ratio (uPCR).

Main Results:

• 88% of patients achieved immunological remission (IR) within 8 weeks.
• 21 patients achieved proteinuria remission after initial therapy; all 7 requiring re-treatment responded.
• Higher baseline PLA2Rab titers and longer PLA2Rab half-life (T1/2) > 7 days were associated with insufficient response and need for additional therapy.
• Serious adverse events occurred in 4 patients; most adverse events were mild, with leukopenia being most frequent.

Conclusions:

• Low-dose triple therapy rapidly induces IR and CR in the majority of high-risk MN patients.
• Early assessment of PLA2Rab levels (2-4 weeks) can identify patients requiring more intensive treatment strategies.
• This approach offers a promising alternative for managing challenging cases of membranous nephropathy.